Remix Therapeutics Employee Directory

Biotechnology ResearchMassachusetts, United States11-50 Employees

Remix Therapeutics is a clinical-stage biotechnology company focused on reprogramming RNA processing with small-molecule therapies to address disease drivers at their origin, targeting conditions with high unmet medical need. Based in Watertown, Massachusetts, the company develops orally administered compounds intended to influence gene expression through RNA processing, aligning with a research-focused positioning in the biotechnology sector.

The lead candidate, REM-422, is described as a first-in-class RNA processing modulator currently in Phase 1 trials for acute myeloid leukemia, high-risk myelodysplastic syndrome, and adenoid cystic carcinoma. In 2026, Remix reported that final results from the Phase 1 dose-escalation portion of the ARIA study in ACC were accepted for an oral presentation at the ASCO Annual Meeting. The company focuses on therapies that address disease at its origin, with an emphasis on oncology and other conditions characterized by high unmet medical needs.

Sign up for free to view info

Company overview Email format